Fungal arthritis and osteomyelitis are rare and documented mainly in immunocompromised or neutropenic patients. Patients receiving therapeutic immunosuppression for organ transplants have also reported to suffer from aspergillus osteoarthritis. We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation. Both were suffering from acute and chronic GVHD and treated with heavy immunosuppression including steroids and cyclosporine. Interestingly in one of our patients, the arthritis was almost asymptomatic and did not spread to other organs. Heavy preand post-transplant immunosuppression is a major risk factor for invasive fungal infection, which can involve remote organs and manifest in an indolent and atypical manner. Bone Marrow Transplantation (2001) 27, 659-661. Keywords: non-myeloablative; aspergillus; arthritis; immunosuppression Potent immunosuppression is an important part of pre-BMT conditioning. In non-myeloablative stem cell transplantation (NST) it enables engraftment without myeloablation, thus significantly decreasing chemotherapy and radiationrelated toxicity. 1 Unfortunately, immunosuppression induced by either method of BMT may facilitate deep fungal infection.
Potent immunosuppression is an important part of pre-BMT conditioning. In non-myeloablative stem cell transplantation (NST) it enables engraftment without myeloablation, thus significantly decreasing chemotherapy and radiationrelated toxicity. 1 Unfortunately, immunosuppression induced by either method of BMT may facilitate deep fungal infection. 2 Furthermore, patients who develop acute or chronic GVHD, which themselves are immunosuppressive, are being further immunosuppressed with cyclosporine and high-dose steroids and are particularly vulnerable to infectious complications. We describe two patients with GVHD who developed aspergillus arthritis after fludarabine-based non-myeloablative stem cell transplantation, of whom one was almost asymptomatic and experienced no clinically significant systemic spread. 
Case reports

Patient 1
A 35-year-old man with SAA was admitted for a one-locus mismatched NST from his sister, after failure of conservative treatment. Pre-transplantation conditioning included i.v. fludarabine (30 mg/m 2 ϫ 6 days), i.v. cyclophosphamide (60 mg/kg ϫ 2 days) followed by i.v. anti-thymocyte globulin (ATG) (10 mg/kg ϫ 4 days). Intravenous cyclosporine (3 mg/kg/day) was used as anti-GVHD prophylaxis. Engraftment was fast, with a total white count Ͼ1 ϫ 10 9 /l on day ϩ11, absolute neutrophil count Ͼ0.5 ϫ 10 9 /l on day ϩ11, and platelet count Ͼ25 ϫ 10 9 /l on day ϩ20. The patient was discharged well, but was readmitted on day ϩ180 due to severe chronic skin and gastrointestinal GVHD which peaked on day ϩ210 despite immunosuppressive treatment with i.v. cyclosporine and i.v. methylprednisolone. On day ϩ320 he developed large bilateral knee joint effusions accompanied by unilateral knee pain. Physical examination disclosed large, bilateral knee effusions with unilateral left knee tenderness on movement, with no obvious signs of arthritis. In spite of this pain, the patient was capable of standing and walking. Diagnostic and therapeutic arthrocentesis from the left knee was performed, with temporary control of the pain. Synovial fluid examination disclosed turbid fluid with multiple granulocytes but without any apparent presence of infectious agents. Total protein level in the synovial fluid was 25 g/l, LDH 1429 U/l, glucose 8.3 mmol/l and pH 6.7. A week later left knee arthrocentesis was again performed due to reaccumulation of the fluid. Two weeks afterward he developed rapidly progressing sepsis and died despite supportive care and broad-spectrum antibiotics. An autopsy was not carried out. The synovial fluid culture from both samples was positive for Aspergillus fumigatus 25 days after it was set up (and after his death). Even retrospectively, he had had no other organ involvement by aspergillus.
Patient 2
A 45-year-old man suffered from resistant AML M-2. After two courses of induction chemotherapy (1st: daunorubicin, VP-16, cytosine arabinoside (Ara-c); and 2nd: mitoxan-trone ϩ high-dose Ara-c) in a short space of time he entered partial remission (15% blasts in the bone marrow). He then underwent NST from his fully HLA matched sister. The conditioning protocol included i.v. fludarabine (30 mg/m 2 ϫ 6 days), p.o. busulfan (4 mg/kg ϫ 4 days) and i.v. ATG (5 mg/kg ϫ 4 days). Intravenous cyclosporine (3 mg/kg/day) was used as anti-GVHD prophylaxis. Engraftment was fast and the post-transplant course was uneventful until day ϩ38 when he developed acute grade IV GVHD of the skin and intestinal tract. Intravenous methylprednisolone (2 mg/kg/day) followed by oral thalidomide (100 mg ϫ 4/day) were added to the GVHD treatment with some improvement. The patient was stable on this treatment until day ϩ90 when he developed a painful monoarthritis of the left knee. Arthrocentesis was preformed and synovial fluid examination disclosed a pus-like fluid with multiple granulocytes and septate hyphae with dichromatous branching. Subsequently, the patient developed pleural effusions, cortical blindness and a left hemiparesis. CT of the brain was highly suspicious of fungal lesions. The pleural fluid was tapped and was followed by respiratory failure leading to death 10 days after his admission (102 days post NST) in spite of treatment with amphotericin B. An autopsy was not carried out. Plural fluid and fluid from both knee joints were all positive for Aspergillus fumigatus.
Discussion
Arthritis in patients after bone marrow transplantation is rare, 3 although bone pain is frequent. It may present as mono, oligo or polyarthritis. The most common causes are GVHD (usually in its chronic phase accompanied by scleroderma or a Sjogren's like syndrome) 4 relapse of the underlying disease 5 or infection. Other rare causes such as serum sickness 6 or prostaglandin E1-induced arthritis 7 have been described. A more common cause for arthralgia (without arthritis) in this setting, is avascular necrosis, 8 which is often due to chronic high-dose steroid therapy. In cases of infective arthritis, the causative agent is usually bacterial but can occasionally be viral. 9 Disseminated or sino-pulmonary aspergillosis is common after allogeneic BMT, especially in the setting of mismatched or unrelated transplantation or GVHD. 2 Fludarabine, the purine analogue used in most non-myeloablative protocols is a potent immunosuppressor and has been associated with an increase in infections involving T cell dysfunction, such as listeriosis, pneumocystis, mycobacterial infections, and opportunistic fungal and viral infections. 10 The frequency of invasive fungal infections in autologous BMT is lower.
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In contrast to the frequently reported systemic aspergillus infections isolated aspergillus arthritis has not been reported in this setting, to our knowledge. This may be due to the very invasive nature of aspergillus, which tends to manifest either with pulmonary or systemic involvement.
Rare cases of localized aspergillus osteoarthritis have been reported in patients with prosthetic joints despite their normal immune status. 12 There are also occasional reports of isolated aspergillus arthritis in immuno-compromised patients such as those receiving renal, 13, 14 or heart-lung transplants 15 and those with acute lymphoblastic leukemia 16 and cirrhosis. 17 Gardella et al 18 reported a case of fungal arthritis in a patient post BMT caused by Trichosporon beigelii. However, the arthritis was part of a systemic fungemia.
In the first patient described here, on-going antifungal prophylaxis with amphotericin B (1 mg/kg every other day started from 1 month prior to his death and given until 1 week prior to his death), may be the reason for the localization of the infection to a poorly vascularized site, namely the knee joint. The relative indolence of the disease in this patient may relate to its chronic evolution and the potent immunosuppressive therapy, particularly the high-dose steroids.
We conclude that arthritis can be a presenting sign of systemic or localized fungal infection, especially in an immuno-compromised patient. Thus, any immuno-compromised patient, irrespective of neutrophil count, who develops a joint effusion even without obvious signs of arthritis, should be investigated thoroughly to exclude the possibility of fungal infection.
